Prothena Corporation PLC (PRTA) Earns Outperform Rating from Analysts at Evercore ISI
Equities researchers at Evercore ISI assumed coverage on shares of Prothena Corporation PLC (NASDAQ:PRTA) in a research report issued on Wednesday, The Fly reports. The brokerage set an “outperform” rating on the biotechnology company’s stock.
Several other analysts have also recently weighed in on PRTA. ValuEngine cut Prothena Corporation PLC from a “sell” rating to a “strong sell” rating in a report on Saturday, May 27th. Zacks Investment Research cut Prothena Corporation PLC from a “buy” rating to a “hold” rating in a report on Monday, May 15th. Oppenheimer Holdings, Inc. set a $70.00 price target on Prothena Corporation PLC and gave the company a “buy” rating in a report on Thursday, May 11th. Jefferies Group LLC started coverage on Prothena Corporation PLC in a report on Monday, July 10th. They issued a “buy” rating and a $100.00 price target on the stock. Finally, BTIG Research started coverage on Prothena Corporation PLC in a report on Friday, May 19th. They issued a “buy” rating and a $80.00 price target on the stock. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Prothena Corporation PLC presently has a consensus rating of “Buy” and an average target price of $77.09.
Shares of Prothena Corporation PLC (PRTA) traded down 0.74% on Wednesday, hitting $57.69. The company had a trading volume of 136,975 shares. Prothena Corporation PLC has a 1-year low of $40.58 and a 1-year high of $69.53. The firm’s market capitalization is $2.21 billion. The company has a 50 day moving average price of $60.53 and a 200 day moving average price of $55.14.
Prothena Corporation PLC (NASDAQ:PRTA) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.43. The business had revenue of $26.81 million for the quarter, compared to analysts’ expectations of $16.08 million. Prothena Corporation PLC had a negative return on equity of 33.20% and a negative net margin of 527.56%. The firm’s quarterly revenue was up 7951.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.18) EPS. On average, equities analysts forecast that Prothena Corporation PLC will post ($4.54) earnings per share for the current fiscal year.
In other news, insider Karin L. Walker sold 5,000 shares of the stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $64.89, for a total transaction of $324,450.00. Following the transaction, the insider now directly owns 5,000 shares in the company, valued at approximately $324,450. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Dennis J. Selkoe sold 3,500 shares of the stock in a transaction dated Friday, July 7th. The shares were sold at an average price of $58.11, for a total value of $203,385.00. Following the transaction, the director now owns 6,345 shares in the company, valued at $368,707.95. The disclosure for this sale can be found here. 3.10% of the stock is currently owned by corporate insiders.
Several institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can raised its position in shares of Prothena Corporation PLC by 6.7% in the second quarter. Bank of Montreal Can now owns 1,858 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 117 shares during the period. Quantbot Technologies LP raised its position in shares of Prothena Corporation PLC by 672.7% in the second quarter. Quantbot Technologies LP now owns 1,870 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 1,628 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Prothena Corporation PLC by 187.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,375 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 1,549 shares during the period. Ameritas Investment Partners Inc. purchased a new position in shares of Prothena Corporation PLC during the first quarter valued at approximately $167,000. Finally, Sei Investments Co. purchased a new position in shares of Prothena Corporation PLC during the second quarter valued at approximately $176,000.
Prothena Corporation PLC Company Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.